Ruth March is Senior Vice President, Precision Medicine & Biosamples, R&D Oncology, at AstraZeneca.
Ruth March is an experienced Board member, senior industry leader, and scientific investment advisor with experience in biopharmaceuticals, diagnostics, genomics, and precision medicine. She combines deep scientific and technical expertise with board and committee experience in both private and public sectors.
As Senior Vice President of Precision Medicine and Biosamples, she is accountable for the development of novel companion and complementary diagnostics for AstraZeneca’s drug projects in all therapy areas and phases of drug development, leads more than 240 diagnostics and biosamples experts globally, and has successfully launched 48 diagnostic tests for five Precision Medicine drugs.